Indirect treatment comparison

A defensible ITC or NMA, prepared to support HTA submission.

Proof·Documents and packs

Shortlist it, send it over — we come back with the shape we'd actually recommend.

What it is

What indirect treatment comparison actually is.

A defensible indirect treatment comparison or network meta-analysis. Feasibility, network construction, the analysis itself and a reviewer-ready technical report prepared to support the HTA submission. Feasibility comes first: where the network will not support a robust comparison, we say so rather than force one.

Built for access and HEOR teams where the head-to-head comparator does not exist and the agency will ask for an indirect comparison whether the team plans for it or not.

What you get
  • Technical ITC / NMA report ready for HTA submission
  • Trial network with included and excluded studies and the reasons
  • Pooled comparative effects with diagnostics
  • Sensitivity and subgroup runs
  • Reviewer-ready reproducibility pack (model card, code, trial set)
Build a scope of work

Add the pieces you'd want and we'll build a shortlist you can review, reorder and send over. No pricing wall, no commitment — we come back with what we'd actually recommend, including anything you don't need.

How it works

Approach, modules, delivery.

Move through the tabs to see how the work runs, what it's made of and what lands at the end.

Inputs

  • Eligible trial evidence (sponsor + comparators)
  • Individual-patient data where available
  • HTA agency methods guidance for indirect comparisons

Method

A defined engagement covering feasibility, network construction and the analysis itself. We test whether a connected network exists, build it with conservative assumptions, run the analysis (Bayesian or frequentist depending on the network), and deliver a technical report that drops directly into HTA submissions. Sensitivities and model fit are surfaced explicitly.

Assumptions

  • Eligible comparator trials report enough outcome detail to enter the network.
  • HTA agency in scope accepts indirect comparison as evidence in this disease area.

Limitations

  • Network connectivity is a constraint we name early; thin networks return wide credible intervals.
Scope builder

Think this belongs in your scope?

Add it alongside anything else that fits, then send the shortlist over. We'll reply with the shape we'd recommend — sequence included, and the parts we think you can skip.

Build what comes next.

Whether you need growth, answers or capability, VISFO helps you move earlier and faster.